Ab­b­Vie adds to its neu­ro pipeline with a $1B buy­out deal, bolt­ing on a new drug aimed at Alzheimer’s

Ab­b­Vie is beef­ing up its neu­ro pipeline with a small biotech buy­out that adds a new ap­proach to cog­ni­tive de­cline in Alzheimer’s and oth­er CNS dis­eases.

The phar­ma gi­ant is snap­ping up Bel­gium’s Syn­de­si Ther­a­peu­tics, which 4 years ago land­ed rights to UCB’s synap­tic vesi­cle pro­tein 2A (SV2A) pro­gram aimed at synap­tic ef­fi­cien­cy. The drug tar­gets the com­mu­ni­ca­tion be­tween neu­rons in the brain — which be­comes dys­func­tion­al with the ad­vance of a va­ri­ety of de­gen­er­a­tive ail­ments, most no­tably Alzheimer’s.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER